account_id none on file
legal_name OnKure Therapeutics, Inc.
ticker OKUR
cik 1637715
domain onkuretherapeutics.com
linkedin_company_url https://www.linkedin.com/company/onkure-tx/
entry_point_account_id none on file
name OnKure Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 1 family 0
why_nownone on file
callsnone on file
filings
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates if approved.
filing / Aug 4, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may lower the pricing of competitor products or procedures, which in turn may constrain the pricing of our product candidates, if approved, and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.
filing / Aug 4, 2026 / receipt
The Company’s operating lease agreements are primarily for office space and research labs. For operating leases with a term greater than one year, the Company recognizes the right-of-use (“ROU”) assets and lease liabilities related to the lease payments on its balance sheet.
filing / Aug 4, 2026 / receipt
In the Merger with Reneo, the Company assumed the lease in Irvine, California, where it leases office space under a lease agreement that expires in November 2026 (the “Irvine lease”).
filing / Aug 4, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates if approved.
filing / May 5, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may lower the pricing of competitor products or procedures, which in turn may constrain the pricing of our product candidates, if approved, and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.
filing / May 5, 2026 / receipt
The Company’s operating lease agreements are primarily for office space and research labs. For operating leases with a term greater than one year, the Company recognizes the right-of-use (“ROU”) assets and lease liabilities related to the lease payments on its balance sheet.
filing / May 5, 2026 / receipt
In the Merger with Reneo, the Company assumed the lease in Irvine, California, where it leases office space under a lease agreement that expires in November 2026 (the “Irvine lease”).
filing / May 5, 2026 / receipt
executives
| Michael P. Cruse | Chief Operating Officer | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2022-03-07 | Chief Operating Officer, appointed | sec_8k |
mcp_package_hint
slug onkure-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$